Literature DB >> 11358438

Bcl-2 and GDNF delivered by HSV-mediated gene transfer act additively to protect dopaminergic neurons from 6-OHDA-induced degeneration.

A Natsume1, M Mata, J Goss, S Huang, D Wolfe, T Oligino, J Glorioso, D J Fink.   

Abstract

Previous studies have demonstrated that either the neurotrophin glial-derived neurotrophic factor (GDNF) or the antiapoptotic peptide Bcl-2 delivered into striatum by a viral vector protects dopaminergic neurons of the substantia nigra in vivo from degeneration induced by the administration of the neurotoxin 6-hydroxydopamine (6-OHDA). In this study we used recombinant, replication-incompetent, genomic herpes simplex virus-based vectors to deliver the genes coding for Bcl-2 and GDNF into rat substantia nigra (SN) 1 week prior to 6-OHDA injection into the striatum. Vector-mediated expression of either Bcl-2 or GDNF alone each resulted in a doubling in cell survival as measured by retrograde labeling with fluorogold (FG) and a 50% increase in tyrosine hydroxylase-immunoreactive (TH-IR) neurons in the lesioned SN compared to the unlesioned side. Gene transfer of Bcl-2 and GDNF were equivalent in this effect. Coadministration of the Bcl-2-expressing vector with the GDNF-expressing vector improved the survival of lesioned SN neurons as measured by FG labeling by 33% and by the expression of TH-IR by 15%. These results suggest that the two factors delivered together act in an additive fashion to improve DA cell survival in the face of 6-OHDA toxicity. Copyright 2001 Academic Press.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11358438     DOI: 10.1006/exnr.2001.7671

Source DB:  PubMed          Journal:  Exp Neurol        ISSN: 0014-4886            Impact factor:   5.330


  20 in total

1.  Dual-gene, dual-cell type therapy against an excitotoxic insult by bolstering neuroenergetics.

Authors:  Tonya M Bliss; Miranda Ip; Elise Cheng; Masabumi Minami; Luc Pellerin; Pierre Magistretti; Robert M Sapolsky
Journal:  J Neurosci       Date:  2004-07-07       Impact factor: 6.167

Review 2.  Herpes simplex virus-based vectors.

Authors:  Robin Lachmann
Journal:  Int J Exp Pathol       Date:  2004-10       Impact factor: 1.925

3.  HSV Recombinant Vectors for Gene Therapy.

Authors:  Roberto Manservigi; Rafaela Argnani; Peggy Marconi
Journal:  Open Virol J       Date:  2010-06-18

4.  Transgene expression in the striatum following intracerebral injections of DNA nanoparticles encoding for human glial cell line-derived neurotrophic factor.

Authors:  A M Fletcher; T H Kowalczyk; L Padegimas; M J Cooper; D M Yurek
Journal:  Neuroscience       Date:  2011-08-04       Impact factor: 3.590

5.  The growth compromised HSV-2 mutant DeltaRR prevents kainic acid-induced apoptosis and loss of function in organotypic hippocampal cultures.

Authors:  Michael D Gober; Jennifer M Laing; Scott M Thompson; Laure Aurelian
Journal:  Brain Res       Date:  2006-10-03       Impact factor: 3.252

6.  Functional repression of cAMP response element in 6-hydroxydopamine-treated neuronal cells.

Authors:  Elisabeth M Chalovich; Jian-hui Zhu; John Caltagarone; Robert Bowser; Charleen T Chu
Journal:  J Biol Chem       Date:  2006-04-18       Impact factor: 5.157

7.  Long-term transgene expression in mouse neural progenitor cells modified with phiC31 integrase.

Authors:  Annahita Keravala; Brandi K Ormerod; Theo D Palmer; Michele P Calos
Journal:  J Neurosci Methods       Date:  2008-06-17       Impact factor: 2.390

Review 8.  Gene therapy targeting mitochondrial pathway in Parkinson's disease.

Authors:  Chi-Jing Choong; Hideki Mochizuki
Journal:  J Neural Transm (Vienna)       Date:  2016-09-16       Impact factor: 3.575

9.  Neuroprotective effects of selegiline on rat neural stem cells treated with hydrogen peroxide.

Authors:  Alireza Abdanipour; Iraj Jafari Anarkooli; Saeed Shokri; Mehrdad Ghorbanlou; Vahid Bayati; Reza Nejatbakhsh
Journal:  Biomed Rep       Date:  2017-11-22

Review 10.  Programmed cell death in Parkinson's disease.

Authors:  Katerina Venderova; David S Park
Journal:  Cold Spring Harb Perspect Med       Date:  2012-08-01       Impact factor: 6.915

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.